Pivekimab Sunirine Generates Responses in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm
September 5th 2022Phase 2 findings from the CADENZA trial suggest that pivekimab sunirine may be effective against blastic plasmacytoid dendritic cell neoplasm, a rare and aggressive form of hematologic cancer.
FDA OKs Omidubicel Priority Review For Patients in Need of Allogeneic HSCT
August 7th 2022The biologics license application for omidubicel has been granted priority review and will be assessed as a potential treatment for patients with blood cancer who require allogeneic hematopoietic stem cell transplant.
Secondary Cytoreductive Surgery Only Offers Benefit to Select Patients With Ovarian Cancer
February 2nd 2022An expert with Stanford Health comments on the potential value of secondary cytoreductive surgery for patients with recurrent ovarian cancer and the need for careful patient selection when considering this treatment strategy.
Liso-Cel Outperforms Standard Therapy in Improving QoL in Relapsed/Refractory LBCL
December 29th 2021A comparative analysis indicated that lisocabtagene maraleucel generated superior quality of life in patients with relapsed/refractory large B-cell lymphoma compared with the current standard of care.